TY - JOUR
T1 - A phase I and pharmacokinetic study of ecteinascidin-743 on a daily × 5 schedule in patients with solid malignancies
AU - Villalona-Calero, Miguel A.
AU - Eckhardt, S. Gail
AU - Weiss, Geoffrey
AU - Hidalgo, Manuel
AU - Campbell, Elizabeth
AU - Kraynak, Maura
AU - Von Hoff, Daniel D.
AU - Rowinsky, Eric K.
AU - Beijnen, Jos H.
AU - Van Kesteren, Charlotte
AU - Rosing, Hilde
AU - Lopez-Lazaro, Luis
AU - Guzman, Cecilia
AU - Jimeno, Jose
PY - 2002
Y1 - 2002
N2 - Purpose: The purpose of this study was to (a) assess the feasibility of administering ecteinascidin-743 (ET-743), a novel DNA minor-groove disrupting agent of marine origin, administered as a daily i.v. infusion for 5 days every 3 weeks; (b) recommend a dose for Phase II studies; (c) characterize its pharmacokinetic behavior; and (d) seek preliminary evidence of anticancer activity. Experimental Design: Patients with advanced solid malignancies were treated with escalating doses of ET-743 as a daily 1-h i.v. infusion for 5 days every 3 weeks. Plasma and urine were sampled on both days 1 and 5 of the first course. Pharmacokinetic parameters were related to the principal toxicities. Results: Forty-two patients were treated with 118 courses of ET-743 at doses ranging from 6 to 380 μg/m2/day. Elevations in hepatic transaminases were common at ET-743 dose levels ≥216 μg/m2/day, resolved rapidly, and were never dose limiting nor cumulative. Instead, hematological toxicity was the principal toxicity that precluded dose escalation. The maximum tolerated dose of ET-743 that could be administered repetitively was 325 μg/m2/day. Antitumor activity was noted in three patients with leiomyosarcoma and primary peritoneal and ovarian carcinomas. The pharmacokinetics of ET-743 were dose independent, and drug accumulation over the 5 days of treatment was modest, with the ratio of the area under the plasma-versus-time curve on day 5 to that on day 1 averaging 2.05. The volume of distribution at steady state was large (mean, 1037 liters/m2), and the mean terminal half life on day 5 was 26.81 h. Conclusions: The maximum tolerated dose of ET-743 that can be administered repetitively is 325 μg/m2/day daily × 5 every 3 weeks, which is recommended for disease-directed clinical trials. The acceptable toxicity profile of ET-743 on the divided-dose schedule evaluated in this trial, as well as the generally superior antitumor activity associated with divided-dose schedules in preclinical studies, provides a rationale for further evaluation of ET-743 on this administration schedule.
AB - Purpose: The purpose of this study was to (a) assess the feasibility of administering ecteinascidin-743 (ET-743), a novel DNA minor-groove disrupting agent of marine origin, administered as a daily i.v. infusion for 5 days every 3 weeks; (b) recommend a dose for Phase II studies; (c) characterize its pharmacokinetic behavior; and (d) seek preliminary evidence of anticancer activity. Experimental Design: Patients with advanced solid malignancies were treated with escalating doses of ET-743 as a daily 1-h i.v. infusion for 5 days every 3 weeks. Plasma and urine were sampled on both days 1 and 5 of the first course. Pharmacokinetic parameters were related to the principal toxicities. Results: Forty-two patients were treated with 118 courses of ET-743 at doses ranging from 6 to 380 μg/m2/day. Elevations in hepatic transaminases were common at ET-743 dose levels ≥216 μg/m2/day, resolved rapidly, and were never dose limiting nor cumulative. Instead, hematological toxicity was the principal toxicity that precluded dose escalation. The maximum tolerated dose of ET-743 that could be administered repetitively was 325 μg/m2/day. Antitumor activity was noted in three patients with leiomyosarcoma and primary peritoneal and ovarian carcinomas. The pharmacokinetics of ET-743 were dose independent, and drug accumulation over the 5 days of treatment was modest, with the ratio of the area under the plasma-versus-time curve on day 5 to that on day 1 averaging 2.05. The volume of distribution at steady state was large (mean, 1037 liters/m2), and the mean terminal half life on day 5 was 26.81 h. Conclusions: The maximum tolerated dose of ET-743 that can be administered repetitively is 325 μg/m2/day daily × 5 every 3 weeks, which is recommended for disease-directed clinical trials. The acceptable toxicity profile of ET-743 on the divided-dose schedule evaluated in this trial, as well as the generally superior antitumor activity associated with divided-dose schedules in preclinical studies, provides a rationale for further evaluation of ET-743 on this administration schedule.
UR - http://www.scopus.com/inward/record.url?scp=0036154945&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036154945&partnerID=8YFLogxK
M3 - Article
C2 - 11801542
AN - SCOPUS:0036154945
SN - 1078-0432
VL - 8
SP - 75
EP - 85
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 1
ER -